iifl-logo

Glenmark Pharmaceuticals Ltd AGM

1,514.75
(2.43%)
Mar 21, 2025|12:00:00 AM

Glenmark Pharma. CORPORATE ACTIONS

21/03/2024calendar-icon
21/03/2025calendar-icon
PurposeAGM DateAnnouncement Date
AGM27 Sep 202430 Aug 2024
AGM 27/09/2024 Please find attached herewith proceedings of 46th Annual General Meeting (As Per BSE Announcement Dated on: 27/09/2024)

Glenmark Pharma.: Related News

Glenmark Expands US Portfolio with Acetylcysteine Injection Launch
3 Mar 2025|09:57 PM

Acetylcysteine Injection will be launched in 6 gm/30 mL (200 mg/mL) single-dose vials, and will be made available to hospitals and other system-wide healthcare providers.

Read More
Glenmark Pharma Settles US Legal Dispute Over Generic Zetia
24 Feb 2025|04:15 PM

The lawsuits included one on a generic version of Zetia, a cholesterol drug, as well as four other lawsuits involving Vytorin, a combination drug that contains Zetia.

Read More
Glenmark Pharma Q3 Revenue Jumps 35% to ₹3,388 Crore
16 Feb 2025|10:34 PM

EBITDA surged to ₹600.3 crore, up from a loss of ₹208.7 crore in the year-ago quarter, indicating better operational efficiency

Read More
Glenmark Hit with ₹121.25 Crore Tax Demand, Company to Appeal
10 Feb 2025|09:25 AM

It also appropriates ₹5.86 crore that Glenmark had already paid for surrendering IGST refunds relating to non-realisation of export proceeds.

Read More
Glenmark Launches Generic Glaucoma Drug
27 Nov 2024|12:23 PM

According to a statement from the firm, the Travoprost ophthalmic solution (0.004% ionic buffered solution) is both bioequivalent and therapeutically equivalent to the reference listed medication

Read More
Glenmark Pharmaceuticals Posts ₹354.4 Crore Profit in Q2
18 Nov 2024|10:45 AM

The company also reported revenue from operations to ₹3433.7 Crore. The EBITDA margin for the quarter that ended on September 30, 2024 stands at 17.5%.

Read More
Glenmark Recalls US Products Over Manufacturing Issues
14 Oct 2024|01:22 PM

Glenmark Pharmaceuticals Inc, USA, issued a countrywide (US) Class II recall on September 24 this year.

Read More
Glenmark Pharmaceuticals' Aurangabad Facility Passes FDA Inspection
23 Sep 2024|01:08 PM

This positive outcome indicates compliance with FDA standards and enhances Glenmark's credibility in the pharmaceutical sector.

Read More
Glenmark Shares Surge on Positive FDA Inspection
23 Sep 2024|12:55 PM

In conclusion, the US Food and Drug Administration (USFDA) has issued Form 483 with no observations.

Read More
Top 10 stocks for today – 23rd September 2024
23 Sep 2024|09:34 AM

Here are some of the stocks that may see significant price movement today: HFCL, Aster DM Healthcare, Tata Steel, Glenmark Pharma, etc.

Read More
Read More

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.